INSMED INC

Insmed’s latest moves—price target hike, 85 employee grants and a Duchenne study partnership—boost rare‑disease growth, cost control and payer alignment, positioning the company for future gains.

Insmed’s valuation rises as Bank of America lifts its price target to $211, backed by strong PAH trial results and a 85‑hire talent boost, signaling growth potential in rare‑disease therapeutics.

Insmed Inc. reports 2025 earnings, $78.4 m Q4 revenue, and a $1 billion 2026 sales target for Brinsupri®, amid Arikayce pipeline progress and robust investor outlook.

Insmed Inc. reports Q4 2025 earnings, highlights Brinsupri’s breakthrough 52‑week efficacy in PNH, and outlines a $30‑$35 M 2026 revenue target.

Insmed’s 2025 results reveal a $1.25 B revenue dip as R&D ramps up, yet its rare‑disease pipeline and value‑based contracts promise a rebound—what this means for investors.

Insmed’s analyst upgrades and institutional buying signal confidence in its rare‑disease pipeline, spotlighting promising anti‑GM‑CSF and gene‑editing programs poised for regulatory fast‑track approval.

Insmed’s Q1 sales of Brinsupri and Arikayce beat forecasts, backing strong cash flow and a high‑growth pipeline for ILD and inhaled antibiotics, positioning the company for 2026+ success.

Insmed’s Phase 2b BiRCh trial setback drops stock price, yet Gold‑Man and Truist keep a buy rating and call‑option volume rises—signaling cautious optimism for future upside.

Insmed’s brensocatib failure slashes CRS prospects, but AT‑101, precision‑medicine, and M&A plans keep its growth engine revving—track the shift to stay ahead.

Insmed’s brensocatib trial failure hit shares 20 %‑down, but the company’s new IL‑33 antibody acquisition could diversify its portfolio and unlock cross‑disease growth.